Tropifexor (LJN452) is primarily investigated for its potential in treating liver-related conditions, particularly non-alcoholic steatohepatitis (NASH). It works as a selective farnesoid X receptor (FXR) agonist, which helps regulate bile acid, lipid, and glucose metabolism. By activating FXR, it reduces liver inflammation, fibrosis, and fat accumulation, making it a promising candidate for managing NASH and other metabolic liver diseases. Clinical trials are ongoing to evaluate its efficacy and safety in improving liver function and addressing the underlying causes of these conditions. Additionally, its role in modulating metabolic pathways suggests potential applications in treating related disorders such as type 2 diabetes and hyperlipidemia.